{"id":"https://openalex.org/W2600468751","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","title":"A phase IB study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.","display_name":"A phase IB study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.","publication_year":2012,"publication_date":"2012-05-20","ids":{"openalex":"https://openalex.org/W2600468751","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","mag":"2600468751"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.15_suppl.8594","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110574162","display_name":"Corina Andresen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corina Andresen","raw_affiliation_strings":["Eisai, Woodcliff Lake, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai, Woodcliff Lake, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jennifer Mink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Mink","raw_affiliation_strings":["Eisai, Woodcliff Lake, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai, Woodcliff Lake, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100678880","display_name":"Min Ren","orcid":"https://orcid.org/0000-0001-8554-3618","observed_orcids":["https://orcid.org/0000-0001-8554-3618"]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Ren","raw_affiliation_strings":["Eisai, Woodcliff Lake, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai, Woodcliff Lake, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106081522","display_name":"James P. O\u2019Brien","orcid":"https://orcid.org/0000-0003-2784-6906","observed_orcids":["https://orcid.org/0000-0003-2784-6906"]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James P. O'Brien","raw_affiliation_strings":["Eisai, Woodcliff Lake, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai, Woodcliff Lake, NJ","institution_ids":["https://openalex.org/I4210151718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031591028","display_name":"Ly M. Nguyen","orcid":"https://orcid.org/0009-0000-8919-7097","observed_orcids":["https://orcid.org/0009-0000-8919-7097"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ly Minh Nguyen","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerald Steven Falchook","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055054082","display_name":"John J. Nemunaitis","orcid":"https://orcid.org/0000-0002-2234-2381","observed_orcids":["https://orcid.org/0000-0002-2234-2381"]},"institutions":[{"id":"https://openalex.org/I4210087725","display_name":"Mary Crowley Cancer Research Center","ror":"https://ror.org/002ksg449","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210087725"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John J. Nemunaitis","raw_affiliation_strings":["Mary Crowley Cancer Research Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mary Crowley Cancer Research Center, Dallas, TX","institution_ids":["https://openalex.org/I4210087725"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"15_suppl","first_page":"8594","last_page":"8594"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5663999915122986,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5663999915122986,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.3734999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.013000000268220901,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.996999979019165},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.984000027179718},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8339999914169312},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7200000286102295},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6840000152587891},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7760000228881836},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6349999904632568},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.878000020980835},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5249999761581421},{"id":"https://openalex.org/keywords/vegfr-inhibition","display_name":"VEGFR inhibition","score":0.6370000243186951},{"id":"https://openalex.org/keywords/fgfr-inhibition","display_name":"FGFR inhibition","score":0.8420000076293945},{"id":"https://openalex.org/keywords/ret-inhibition","display_name":"RET inhibition","score":0.7570000290870667},{"id":"https://openalex.org/keywords/kit-inhibition","display_name":"KIT inhibition","score":0.8939999938011169},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.5910000205039978},{"id":"https://openalex.org/keywords/hypothyroidism","display_name":"hypothyroidism","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.9535735845565796},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9212456345558167},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.7150686979293823},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.686409056186676},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.6403670310974121},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5760610699653625},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5332951545715332},{"id":"https://openalex.org/C2777793932","wikidata":"https://www.wikidata.org/wiki/Q1116229","display_name":"Common Terminology Criteria for Adverse Events","level":3,"score":0.5230154395103455},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.43214672803878784},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34855785965919495},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.27323925495147705},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1931861937046051}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.15_suppl.8594","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.8594","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8299999833106995,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2264854570","https://openalex.org/W2960763219","https://openalex.org/W4400272129","https://openalex.org/W2602091618","https://openalex.org/W4400305634","https://openalex.org/W2507114078","https://openalex.org/W2598953034","https://openalex.org/W2127226854","https://openalex.org/W2590476456","https://openalex.org/W1976033646"],"abstract_inverted_index":{"8594":[0],"Background:":[1],"Lenvatinib":[2,286],"is":[3],"an":[4],"oral":[5],"tyrosine":[6],"kinase":[7],"inhibitor":[8],"targeting":[9],"VEGFR1-3,":[10],"FGFR1-4,":[11],"RET,":[12],"KIT":[13],"and":[14,33,62,101,159,237,256,264],"PDGFR\u03b2.":[15],"In":[16],"phase":[17],"I":[18],"studies":[19],"of":[20,52,55,149,157,163,266,306],"lenvatinib":[21,56,72,79,87,308],"partial":[22,229],"responses":[23,225],"were":[24,47,95,112,176,217,228],"observed":[25],"in":[26,49,136,139,172,219,274,279,291],"melanoma":[27,46],"as":[28,30],"well":[29],"thyroid,":[31],"endometrial,":[32],"renal":[34],"cancers.":[35],"Methods:":[36],"Patients":[37],"(pts)":[38],"with":[39,268,293],"stage":[40,44],"4":[41,120],"or":[42,309],"unresectable":[43],"3":[45,141,175,235],"treated":[48,243],"sequential":[50],"cohorts":[51],"escalating":[53],"doses":[54],"by":[57],"continuous":[58],"once":[59,289],"daily":[60,290],"dosing":[61],"temozolomide":[63],"(TMZ)":[64],"days":[65,300],"1-5":[66],"every":[67,298],"28":[68,299],"days.":[69],"Cohort":[70],"1:":[71,115],"20mg,":[73],"TMZ":[74,82,90,294,310],"100":[75,83],"mg;":[76,84],"cohort":[77,85,114,118,122,140,144,174,234],"2:":[78,119],"24":[80,88,287],"mg,":[81,89],"3:":[86,123],"150":[91,295],"mg.":[92],"Adverse":[93],"events":[94,171,216],"recorded":[96],"according":[97,105],"to":[98,106,143,146,152],"CTCAE":[99],"v3.0":[100],"tumor":[102],"response":[103,267],"assessed":[104],"RECIST":[107,227],"1.0.":[108],"Results:":[109],"32":[110],"pts":[111,138,151,236,242],"treated:":[113],"6":[116],"pts,":[117,121],"22":[124,150],"pts.":[125],"Demographics:":[126],"median":[127,257],"age:":[128],"58;":[129],"males:":[130],"63%.":[131],"Dose":[132],"limiting":[133],"toxicities":[134],"occurred":[135],"0/6":[137],"leading":[142],"expansion":[145],"a":[147,160],"total":[148],"enable":[153],"more":[154],"extensive":[155],"assessment":[156],"toxicity":[158],"preliminary":[161],"estimate":[162],"efficacy.":[164],"The":[165,222],"most":[166],"common":[167],"treatment":[168],"related":[169,311],"adverse":[170],"the":[173],"fatigue:":[177],"50%":[178,182,186],"(gr3:":[179,183,207],"9%),":[180,184],"hypertension:":[181],"proteinuria:":[185],"(no":[187,191,195,199,203,211],"gr3),":[188,192,196,200,204],"vomiting:":[189],"46%":[190,194],"hypothyroidism:":[193],"anorexia:":[197],"41%":[198,202],"nausea:":[201],"diarrhea:":[205],"36%":[206],"5%),":[208],"thrombocytopenia:":[209],"32%":[210],"gr3).":[212],"No":[213],"treatment-related":[214],"gr4":[215],"reported":[218],"these":[220],"categories.":[221],"best":[223],"overall":[224],"per":[226],"responses:":[230],"5/22":[231],"(23%)":[232],"for":[233,240,316],"6/32":[238],"(19%)":[239],"all":[241,245],"at":[244],"dose":[246],"levels.":[247],"Six-month":[248],"progression":[249],"free":[250],"survival":[251],"(PFS)":[252],"rate":[253],"was":[254,259,301,319],"37%":[255],"PFS":[258],"5.4":[260],"months.":[261],"PK/PD":[262],"analysis":[263],"correlation":[265],"genetic":[269],"mutational":[270],"status":[271],"(BRAF":[272],"mutations":[273,278],"31%":[275],"pts;":[276],"NRAS":[277],"19%":[280],"pts)":[281],"will":[282],"be":[283],"presented.":[284],"Conclusions:":[285],"mg":[288,296],"combination":[292,318],"days1-5":[297],"given":[302],"without":[303],"apparent":[304],"worsening":[305],"either":[307],"toxicities.":[312],"Modest":[313],"clinical":[314],"efficacy":[315],"this":[317],"observed.":[320]},"counts_by_year":[{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-04-07T00:00:00"}